Not to give false hope here, but IMO you should follow the OpRegen RPE cell replacement trial being run by Roche/Genentech.

Although not in Stargardts but GA AMD (age-related macular degeneration) for now, I suspect they will expand the trial in future to include other diseases that result in retinal degeneration.

OpRegen is the only therapy that has been able to partially regenerate human retinal tissue and reverse atrophy in an early clinical trial, which is why I'm excited about its prospects. They actually did treat a Vitelliform macula dystrophy patient under compassionate use but we don't have public info on how it went.

Disclosure: equity in Lineage Cell Therapeutics, but am an optometrist and PhD student